Evicenter
MarkdownMedical informationP&T meetings
Lonimecgene renparvovec (TSHA-102)

Rett syndrome

Launch
Not announced
Last updated
199 sources

Section 4 of 6

Clinical evidence

146 evidence topics · 44 sources

Study summaries

REVEAL pivotal

Objective
Location and study date
Registered sites for NCT05606614 (Parts A and B combined)
SiteRegistry record
Duarte, California, United States“City of Hope”
La Jolla, California, United States“UC San Diego”
Oakland, California, United States“UC San Francisco Benioff Children's Hospital”
Chicago, Illinois, United States“Rush University Medical Center”
Baltimore, Maryland, United States“Kennedy Krieger Institute”
Boston, Massachusetts, United States“Boston Children's Hospital”
St Louis, Missouri, United States“Washington University, St. Louis”
Dallas, Texas, United States“UT Southwestern Children's Medical Center”
Montreal, Quebec, Canada“CHU St. Justine”
Study design
Eligibility criteria
Registered inclusion and exclusion criteria
Treatment
Study outcomes
Rationale for using Rett syndrome developmental milestone assessment response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design and comparator: REVEAL Pivotal is a single-arm, open-label trial with no concurrent control. Efficacy is judged against an external null response rate of 6.7% (1 of 15 participants) derived from the Rett Syndrome Natural History Study, with a 33% response rate (5 of 15) as the minimum threshold for success. The natural history analysis cites sham lumbar puncture, functional unblinding from required immunosuppression, and delayed treatment as ethical and methodological obstacles to a controlled design.
  • Derivation of the null: the 28 milestones, the minimum age of 6 years, the time-since-loss rules, and the 6.7% threshold come from analyses of Rett Syndrome Natural History Study data. The highest spontaneous gain rate observed after 6 years of age was 3%, corresponding to 0.45 expected spontaneous responders among 15 participants, and one spontaneous responder (6.7%) was selected as the null threshold because the responder count must be discrete.
  • Baseline and milestone eligibility: a milestone is eligible for gain or regain when medical history confirms that it was never achieved or was lost sufficiently long ago and an in-clinic video assessment confirms that it is not demonstrated. In the RESUME validation study, agreement between the RS-DMA historical caregiver interview and the performative RS-DMA averaged 81.8%, with more than one-third of items at slight or fair agreement.
  • Endpoint validation: the RS-DMA was validated in a non-interventional study of 13 participants. Inter-rater agreement was substantial to excellent for 27 of the 28 milestones and fair for identifying body parts, and 83% of video recordings were rated feasible for central rating. A responder is a participant who gains or regains at least 1 of 28 milestones, so a single milestone of any type meets the definition.
  • Blinding and assessment: only central raters are masked, and only to the timing of each video. Milestone demonstration is a performed task administered in clinic. The 2025 FDA draft guidance states that self-controlled studies can be particularly persuasive when a condition is universally degenerative in all affected individuals and the intervention is expected to lead to improvement, and that objectively measured endpoints that are not effort-dependent are critical to interpreting self-controlled or other non-blinded trials. The natural history data describe a developmental plateau from 6 years of age and slow loss of gross motor skills during Stage III.
  • Secondary endpoints: the key secondary measures are the R-MBA and CGI-I. One publication describes the reliability, validity, and responsiveness profiles of the outcome measures it assessed as mostly incomplete, with no data on meaningful change, and the psychometric study of the clinician-reported MBA called for longitudinal evaluation of the measure.
  • Size, timing, and analysis: 17 females aged 6 to under 22 years were dosed against a planned 15. A BLA may rest on a 6-month interim analysis, while the registered primary outcome runs from baseline through week 52 and the statistical analysis plan names a 12-month primary analysis. The registered primary outcome is worded as a change from baseline in the percentage of responders, which differs from the response rate the sponsor describes. No published protocol or statistical analysis plan was identified.
  • Population and extrapolation: eligibility is limited to females with classic Rett syndrome and a loss-of-function MECP2 variant, excluding atypical Rett syndrome and participants needing invasive ventilation. The sponsor plans to extrapolate efficacy to children aged 2 to under 6 years, an age range in which the natural history analysis reports spontaneous first-time gain of a single milestone as high as 97%.
  • Results and safety reporting: no efficacy results have been reported; topline interim data are expected in the first half of 2027. Safety has been reported in company filings and press releases, mostly pooled with the phase 1/2 and ASPIRE trials (33 participants). One pivotal participant had a treatment-related Grade 2 serious adverse event of peripheral sensory neuropathy about 6 weeks after dosing in July 2026; no adverse event table specific to the pivotal trial was identified.
  • Reporting consistency: the third quarter 2026 Form 10-Q states that the pivotal trial is taking place in the United States, while the combined registry record lists a site in Montreal and the sponsor reported a No Objection Letter from Health Canada before site activation.

ASPIRE

Objective
Location and study date
Registry record: dates, status, and sites
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • ASPIRE is a multicenter, open-label study in which every participant receives TSHA-102. It dosed 4 participants (3 planned) aged 2 to less than 4 years, and the registry lists 3 sites.
  • The registry primary endpoint is the proportion of participants experiencing any treatment-emergent adverse events and serious adverse events from baseline through week 25. The planned BLA is to include a minimum of 3 months of ASPIRE safety data, which is shorter than the 25-week primary safety analysis period and the 5-year follow-up period.
  • No ASPIRE-specific safety results have been reported. The available safety statement pools 33 participants across REVEAL Phase 1/2 (12), REVEAL pivotal (17), and ASPIRE (4) and reports the absence of severe treatment-related serious adverse events and dose-limiting toxicities as of the November 2026 data cutoff; it does not report the type or frequency of other adverse events in the 4 ASPIRE participants.
  • No efficacy results have been reported. Efficacy in children aged 2 to less than 6 years is to be extrapolated from REVEAL pivotal participants aged 6 to less than 22 years in the developmental plateau population. The natural history analysis reports spontaneous first-time gain of a single milestone as high as 97% before 6 years of age, and states that including younger participants without explicit age accounting could increase background spontaneous gain.
  • None of the three trials has dosed children aged 4 to less than 6 years: ASPIRE enrolls children aged 2 to less than 4 years, the 12 REVEAL Part A participants were 6 to 21 years of age at dosing, and REVEAL pivotal enrolls participants aged 6 to less than 22 years.
  • The dose is 1.0 × 10¹⁵ total vector genomes adjusted for brain volume; no description of the scaling method or of the doses administered was identified.
  • The registry states that other protocol-defined inclusion and exclusion criteria may apply, and no published protocol, statistical analysis plan, or description of analysis sets was identified.
  • All information comes from the sponsor's registry record, press releases, and SEC filings and from a natural history analysis. The company's August 2026 corporate presentation describes efficacy data for females aged 2 to less than 4 years as to be extrapolated from the pivotal trial, while the Form 10-K and the third quarter 2026 Form 10-Q describe extrapolation to the 2 to less than 6-year-old population.

REVEAL part A

Objective
Location and study date
Adolescent and adult trial (NCT05606614): registry dates
MilestoneRegistry record
Study start (actual)“2023-03-06”
Primary completion (estimated)“2031-06”
Study completion (estimated)“2031-06”
Last update posted“2026-07-07”
Adolescent and adult trial (NCT05606614): registered sites for Parts A and B
Pediatric trial (NCT06152237): registry dates
MilestoneRegistry record
Study start (actual)“2023-12-12”
Primary completion (estimated)“2028-11-02”
Study completion (estimated)“2031-11-02”
Last update posted“2025-10-15”
Study design
Pediatric trial (NCT06152237): registered design elements
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Individual participants: age at dosing, baseline CGI-S, and follow-up
Cohort and participantAge at dosing (years)Baseline CGI-S scorePost-treatment follow-up (months)
Low dose, participant 1“20”“6”“30”
Low dose, participant 2“21”“4”“30”
Low dose, participant 3“6”“5”“24”
Low dose, participant 4“7”“4”“24”
High dose, participant 1“15”“5”“18”
High dose, participant 2“21”“5”“18”
High dose, participant 3“8”“5”“18”
High dose, participant 4“15”“5”“12”
High dose, participant 5“16”“5”“12”
High dose, participant 6“6”“4”“12”
High dose, participant 7“7”“6”“12”
High dose, participant 8“6”“5”“12”
Efficacy results
Responses at 6, 12, and at least 18 months (May 2026 data cutoff)
Endpoint6 months (N=12)12 months (N=12)18 months or more (N=7)
Participants who gained or regained at least one developmental milestone“83%”“100%”“100%”
Average functional gains per participant“22”“23”“26”
R-MBA mean score change versus natural history“-11.0 P = 0.0011”“-10.3 P = 0.0002”“-11.0 P = 0.0046”
Participants with CGI-I score of 3 or less at multiple post-treatment assessments“100%”“100%”“100%”
Participants with CGI-S total score improvement“25%”“25%”“57%”
Health-related quality of life and patient-reported outcomes
Health-related quality of life instrument results

No evidence found.

Safety results
Treatment-emergent adverse events across the 12 participants (May 2026 data cutoff)
Event categoryLow dose, participantsLow dose, eventsHigh dose, participantsHigh dose, eventsTotal, participantsTotal, events
TEAE related to TSHA-102“4”“17”“5”“20”“9”“37”
Serious TEAE unrelated to TSHA-102“3”“9”“4”“8”“7”“17”
Serious TEAE related to TSHA-102“0”“0”“0”“0”“0”“0”
Study limitations
Summary
  • Pooled sample: REVEAL Part A combines two separately registered phase 1/2 dose-escalation trials, NCT05606614 Part A (females aged 12 to <22 years) and NCT06152237 (females aged 5 to 8 years), into one analysis of 12 participants, 4 at the low dose and 8 at the high dose. Comparisons between doses rest on groups of 4 and 8 participants, and comparisons between age groups on 6 pediatric and 6 adolescent or adult participants.
  • No concurrent control: Part A of both trials is open label, and the 2026 poster describes each participant as their own control. Efficacy is judged against each participant's baseline and against external data from the Rett syndrome Natural History Study. The R-MBA comparison draws on natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA.
  • Efficacy endpoints outside the registered Part A outcomes: the registered primary outcome of Part A in both trials is the proportion or incidence of participants with treatment-emergent adverse events and serious adverse events. Developmental milestone gain or regain, the primary evidence of efficacy in the 2026 poster, is registered as the primary outcome of Part B, and the poster describes evaluation criteria applied to available video-evidenced milestone data. The counts of additional skills derived from the MSEL-A, ORCA, and R-MBA come from a supplemental analysis, with ORCA data for 8 and MSEL-A data for 7 of the 12 participants; an earlier company announcement reported 165 additional skills or improvements across 10 participants from the same scales.
  • Masking: the pediatric trial is registered with no masking. In the adolescent and adult trial, only the central raters of milestone videos are masked, and only to the timing of each video. The R-MBA is a clinician-reported evaluation and ORCA a caregiver-reported evaluation, collected in open-label trials.
  • Follow-up: all 12 participants had at least 12 months of follow-up (range 12 to 30 months), and results at 18 months or more rest on 7 participants.
  • Concomitant immunosuppression: prednisolone and sirolimus begin 7 days before dosing and are tapered over the following months. In the company's 2024 first-cohort data presentation, the most common event, vomiting, was described as a known risk of sirolimus, and eight nonserious events were attributed to immunosuppression.
  • Heterogeneous population: participants were 6 to 21 years of age at dosing, had baseline CGI-S scores of 4 to 6, and carried varied MECP2 mutations; the pediatric trial was opened to stage three Rett syndrome and the adolescent and adult trial to stage four Rett syndrome.
  • Sponsor reporting: all results come from Taysha press releases, SEC filings, presentations, and congress posters, and the 2025 poster states that its data came from the electronic data capture system and were subject to change.
  • Inconsistencies between documents: the low dose was stated as 5x10^14 vg in June 2023 and as 5.7x10^14 vg in the registry and the third quarter 2026 Form 10-Q. The third quarter 2026 Form 10-Q describes both trials as randomized and NCT06152237 lists randomized allocation, while NCT05606614 lists non-randomized allocation, the 2023 pediatric design poster describes Part A as a single-arm dose escalation, and the 2024 first-cohort presentation plans randomization in Part B. The 2024 announcements planned at least 3 participants per dose in the pediatric trial and 3 high-dose participants in the adolescent and adult trial; NCT05606614 enrolled 2 low-dose and 4 high-dose participants, and the 12 Part A participants comprised 4 low-dose and 8 high-dose participants.